

Sho Ikeda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4205791/publications.pdf>

Version: 2024-02-01

15
papers

417
citations

933264

10
h-index

996849

15
g-index

15
all docs

15
docs citations

15
times ranked

723
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6, in advanced cutaneous T-cell lymphoma. <i>Blood</i> , 2014, 123, 1499-1511.	0.6	91
2	Role of microRNA in the pathogenesis of malignant lymphoma. <i>Cancer Science</i> , 2013, 104, 801-809.	1.7	51
3	Hypoxia-inducible KDM3A addiction in multiple myeloma. <i>Blood Advances</i> , 2018, 2, 323-334.	2.5	50
4	Hypoxia-inducible hexokinase-2 enhances antiapoptotic function via activating autophagy in multiple myeloma. <i>Cancer Science</i> , 2020, 111, 4088-4101.	1.7	34
5	Low hexokinase-2 expression-associated false-negative 18F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1345-1350.	3.3	32
6	Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma. <i>Cancer Science</i> , 2017, 108, 641-652.	1.7	31
7	Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 7572-7585.	0.8	27
8	Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas. <i>Haematologica</i> , 2018, 103, 126-135.	1.7	22
9	Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma. <i>Cancer Science</i> , 2021, 112, 3995-4004.	1.7	21
10	Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 13563-13574.	0.8	21
11	Dysregulation of microRNAs and their association in the pathogenesis of T-cell lymphoma/leukemias. <i>International Journal of Hematology</i> , 2014, 99, 542-552.	0.7	10
12	Phase II Clinical Trial of Lenalidomide and Dexamethasone Therapy in Japanese Elderly Patients With Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 301-309.	1.0	9
13	Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence. <i>Cancer Science</i> , 2021, 112, 3645-3654.	1.7	8
14	Downregulation of miR-26 promotes invasion and metastasis via targeting interleukin-22 in cutaneous T-cell lymphoma. <i>Cancer Science</i> , 2022, 113, 1208-1219.	1.7	6
15	Multiparameter Flow Cytometry for the Identification of Neoplastic Plasma Cells in POEMS Syndrome with IgG-kappa Gammopathy: Successful Treatment Using Lenalidomide and Dexamethasone. <i>Internal Medicine</i> , 2019, 58, 3461-3468.	0.3	4